Business
Results for the six months ended 30 June 2025
Futura Medical PLC reported revenue of £1.0 million for the six months ended June 30, 2025, a decrease from £7.0 million in HY24, reflecting slower in-market sales of Eroxon. Underlying gross profit was £0.73 million, excluding a £0.49 million exceptional provision for potential inventory obsolescence. The company experienced a loss after tax of £6.59 million, which included £3.6 million of exceptional items for impairment of plant and equipment and a £0.65 million non-cash charge for share-based payments; the adjusted loss after tax was £2.0 million. Cash and cash equivalents stood at £3.69 million as of June 30, 2025. Revenues for FY 2025 are expected to be between £1.3 million and £1.4 million. Cash and cash equivalents stood at £2.71m at the end of August 2025. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n30 September 2025\n \nFutura Medical plc\n(\"Futura\" or the \"Group\")\nResults for the six months ended 30 June 2025\nFutura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces its results for the six months ended 30 June 2025 (\"HY25\").\n \nOperational overview:\n\n\n\n\n· \n\n\nFurther market launches, with Eroxon now launched in 25 countries, but challenges around usage and marketing communication continue\n\n\n\n\n· \n\n\nEroxon Intense remains on track to achieve regulatory approvals in EU and USA by the end of 2025. Following successful proof of concept work which demonstrated a strong preference for the enhanced sensorial effects of Intense, a more extensive Home User Study in up to 200 UK erectile dysfunction (\"ED\") subjects has been commissioned\n\n\n\n\n· \n\n\nSuccessful completion in January 2025 with positive results of a Home User study on WSD4000, a topical treatment for the symptoms associated with sexual dysfunction in women; a further pre-submission meeting with the FDA has taken place prior to the Early Feasibility Study due in Q1 2026\n\n\n\n\n \nFinancial overview:\n\n\n\n\n· \n\n\nRevenue of £1.0m (HY24: £7.0m) reflecting slower than originally anticipated in market sales of Eroxon meaning initial 2024 inventory orders are still being used, suppressing 2025 demand\n\n\n\n\n· \n\n\nSales in the period comprise 50% royalties from the US market, 48% from products sales in the EU and UK, with the remainder from LATAM and the Middle East\n\n\n\n\n· \n\n\nUnderlying gross profit of £0.73m (HY24: £1.7m) excluding an exceptional provision of £0.49m for potential inventory obsolescence\n\n\n\n\n· \n\n\nLoss after tax of £6.59m (HY24: profit after tax of £1.0m), this includes\n\n\n\n\n\n\n\no\n\n\n£3.6m of exceptional items for impairment of plant and equipment due to lower production demand and the final asset payment due in H2 2025\n\n\n \n\n\n\n\n\n\n\no\n\n\n£0.49m provision for risk of inventory obsolescence\n\n\n ...